Turnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
- SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
- The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.
- “I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer.
- “Will is a highly accomplished biotechnology executive and Board member, and his impressive track record and deep operational and financial acumen make him a valuable addition to our Board.